Emergent BioSolutions (EBS) Misses Q2 EPS, Revenue
Tweet
Share
E-mailGet Alerts EBS Hot Sheet
Price: $8.01 -0.5%
EPS Growth %: -31.3%
Financial Fact:
Selling, general and administrative: 40.69M
Today's EPS Names:
CCEL, MHGU, PLG, More
EPS Growth %: -31.3%
Financial Fact:
Selling, general and administrative: 40.69M
Today's EPS Names:
CCEL, MHGU, PLG, More
Join SI Premium – FREE
Emergent BioSolutions (NYSE: EBS) reported Q2 EPS of ($0.86), $1.24 worse than the analyst estimate of $0.38. Revenue for the quarter came in at $242.7 million versus the consensus estimate of $270.94 million.
For earnings history and earnings-related data on Emergent BioSolutions (EBS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Jefferies upgrades Shopify to Buy on AI commerce tailwinds, sees 30% upside
- Ericsson (ERIC) Tops Q2 EPS by 3c
- Shutterstock CEO Paul Hennessy steps down; CFO named interim chief
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
